StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $75.15 | $76.43 | +1.70% | 1.3M |
| 05-12 | $77.00 | $75.04 | -2.55% | 1.8M |
| 05-13 | $75.69 | $76.31 | +0.82% | 0.8M |
| 05-14 | $76.51 | $75.65 | -1.12% | 0.4M |
| 05-15 | $77.08 | $74.92 | -2.80% | 2.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-209.56M | $-208.57M | $-147.31M | $-91.92M |
Net Income | $-155.20M | $-208.02M | $-151.72M | $-38.84M |
EPS (Diluted) | Not available | Not available | $2.39 | $1.31 |
Total Assets | $777.78M | $608.48M | $421.09M | $436.07M |
Total Liabilities | $62.55M | $90.68M | $93.70M | $61.68M |
Cash & Equivalents | $85.72M | $89.42M | $71.58M | $45.14M |
Free Cash Flow OCF − CapEx | Not available | $-157.41M | Not available | Not available |
Shares Outstanding | 78.19M | 60.26M | 51.40M | 50.78M |